Evidence map›Paper›PMID 39543071›Full record

ArticleJournal of general internal medicine2025

Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic : State Telehealth Policies and Buprenorphine.

Bradley D Stein, Brendan K Saloner, Flora Sheng, Mark Sorbero, Andrew W Dick, Adam J Gordon

Abstract read
In one paragraph

Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bradley D SteinRAND Corporation, Pittsburgh, USA. Stein@rand.org.
Brendan K SalonerJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Flora ShengRAND Corporation, Arlington, VA, USA.
Mark SorberoRAND Corporation, Pittsburgh, USA.
Andrew W DickRAND Corporation, Boston, MA, USA.
Adam J GordonProgram for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceState policies facilitating telehealth implemented early in COVID may support buprenorphine treatment of opioid use disorder. However, little empirical information is available about those policies' effects.

objectiveExamine association between state policies that may facilitate telehealth use and buprenorphine treatment. DESIGN, SETTING,

participantsRetrospective cohort study using 2019-2020 national pharmacy data on dispensed buprenorphine prescriptions. EXPOSURES: State policies implemented after March 3, 2020, public health emergency declaration requiring private insurers' telehealth reimbursement to be commensurate with in-person service reimbursement, authorizing Medicaid reimbursement for audio-only telehealth, allowing physicians to provide cross-state telehealth services, and allowing psychologists to provide cross-state telehealth services. MAIN OUTCOMES AND MEASURES: (a) Duration of treatment episodes started between March 1 and March 13 in both 2019 and 2020, and (b) daily numbers of new buprenorphine treatment episodes from March 13 through December 31 in each year. KEY

resultsWe found little change in the number of new buprenorphine treatment episodes started in 2020 compared to 2019 and an increase in treatment duration of 10.3 days (95%CI 8.3 to 12.2 days) for episodes started in March 2020 before the public health emergency declaration compared to the comparable 2019 period. States implementing a telehealth parity policy in 2020 had 7.3% (95%CI - 13.3% to - 0.4%) fewer new buprenorphine treatment episodes. States joining the psychologist interstate compact in 2020 after the public health emergency declaration had treatment episodes 7.97 days longer (95%CI 0.78 to 15.16) than other states. None of the other policies examined was associated with changes in new treatment episodes or treatment duration. CONCLUSIONS AND RELEVANCE: Policies undertaken during the pandemic we examined were associated with few significant changes in buprenorphine treatment initiation and duration. Findings suggest realizing the benefits of telehealth and other policy changes for buprenorphine may require more extensive implementation and infrastructure support.

Indexed as

BuprenorphineCOVID-19Health PolicyOpiate Substitution TreatmentOpioid-Related DisordersTelemedicineCohort StudiesHumansNarcotic AntagonistsPandemicsRetrospective StudiesState GovernmentUnited StatesBuprenorphineNarcotic AntagonistsBuprenorphineOpioid use disorderState policiesTelehealth

Identifiers

PMID39543071
PMCPMC12325807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.